Digestive and Gastrointestinal Diseases
Advancing Digestive & Gastrointestinal Drug Discovery
Gastrointestinal disorders encompass a wide range of digestive diseases and conditions affecting the esophagus, stomach, pancreas, intestines, and colon. These gastrointestinal diseases include inflammatory bowel disease (IBD), gastric ulcers, pancreatitis, eosinophilic esophagitis, short bowel syndrome, motility disorders, and other digestive disorders that require diverse therapeutic strategies.
WuXi Biology and Testing supports gastrointestinal drug discovery from target validation through IND-enabling studies. By integrating disease biology, translational pharmacology, DMPK, bioanalysis, and safety assessment, we help accelerate the development of therapies across multiple gastrointestinal disorders and therapeutic modalities.
Understanding Gastrointestinal Disease Complexity
The gastrointestinal tract maintains digestive health through tightly coordinated interactions between epithelial barrier function, immune regulation, the gut microbiome, nutrient absorption, motility, and gut–brain signaling. Disruption of these processes contributes to many gastrointestinal disorders, including inflammatory, functional, and structural digestive diseases.
Because disease mechanisms differ across organs and indications, successful gastrointestinal drug discovery requires complementary disease models, translational biomarkers, and functional endpoints that improve understanding of gastrointestinal inflammation, therapeutic response, and clinical translation.
Challenges & Solutions for Digestive and Gastrointestinal Diseases
Challenges
Understanding the biological mechanisms driving gastrointestinal inflammation and immune-mediated digestive diseases while identifying therapies with the potential to modify disease progression.
Solutions
- Disease-relevant cellular and in vivo models
- Immune cell functional assays
- Cytokine and inflammatory biomarker profiling
- Mechanism of action studies
- Translational pharmacology
Challenges
Evaluating therapies designed to restore epithelial integrity, promote mucosal healing, reduce fibrosis, and improve tissue regeneration across diverse gastrointestinal diseases.
Solutions
- Human intestinal organoids and primary cell models
- Barrier integrity and permeability assays
- Fibrosis and tissue remodeling models
- Histopathology and molecular characterization
- Functional biomarker analysis
Challenges
Selecting models that accurately reflect human gastrointestinal diseases and digestive disorders while generating meaningful efficacy and translational data across diverse indications.
Solutions
- Validated in vitro, ex vivo, and in vivo disease models
- Pharmacology studies across acute and chronic GI disease models
- Translational biomarkers and pharmacodynamic endpoints
- Mechanism of action and efficacy evaluation
- Functional and pathological assessments
Challenges
Characterizing drug exposure, pharmacokinetics, and pharmacodynamic relationships to support candidate optimization and clinical translation.
Solutions
- In vitro ADME and pharmacokinetic studies
- Bioanalytical method development and sample analysis
- PK/PD modeling and exposure-response assessment
- Biomarker and ligand-binding bioanalysis
- Support for small molecules, biologics, and emerging therapeutic modalities
Challenges
Identifying potential safety risks while supporting the development of therapies for gastrointestinal disorders and other digestive diseases.
Solutions
- IND-enabling safety assessment
- General toxicology studies
- Safety pharmacology evaluation
- Investigative and mechanistic toxicology
- Integrated pathology and toxicokinetic assessment
Gastrointestinal Disease Models and Translational Pharmacology
Gastrointestinal diseases involve diverse mechanisms, including inflammation, barrier dysfunction, altered motility, impaired absorption, fibrosis, and tissue injury. Disease-relevant models are needed to evaluate efficacy and understand therapeutic response. Our platform combines in vitro, ex vivo, and in vivo models with functional endpoints, histopathology, and translational biomarkers.
Capabilities include:
- Inflammatory bowel disease models
- Gastric ulcer models
- Acute and chronic pancreatitis models
- Eosinophilic esophagitis models
- Short bowel syndrome models
- Constipation and gastrointestinal motility models
- Histopathology and tissue characterization
- Translational biomarker and PK/PD analysis
Human Intestinal Organoids and Advanced Cellular Models
Advanced cellular models provide mechanistic insight into gastrointestinal disease biology and therapeutic response. Human intestinal organoids and primary-cell systems can reproduce important features of epithelial function, inflammation, and tissue repair. These models support target validation, pharmacological evaluation, and candidate selection before in vivo studies.
Capabilities include:
- Human intestinal organoid models
- Primary intestinal epithelial-cell models
- Disease-relevant cellular systems
- Epithelial and immune-cell co-culture models
- Barrier-integrity and permeability assays
- Inflammatory-response and cytokine analysis
- Mechanism-of-action studies
- Functional biomarker assessment
Intestinal Barrier, Absorption, and Motility Assessment
Barrier integrity, nutrient absorption, and gastrointestinal motility are important indicators of digestive health and therapeutic response. Functional studies help determine whether a candidate improves epithelial repair, intestinal absorption, or gastrointestinal transit. These findings can be integrated with pharmacokinetic, biomarker, and pathology data to support development decisions.
Capabilities include:
- Intestinal barrier-integrity assays
- Permeability and absorption studies
- D-xylose absorption testing
- Epithelial repair and mucosal-healing assessment
- Gastric-emptying studies
- Intestinal transit and motility assessment
- Fibrosis and tissue-remodeling evaluation
- Functional and translational biomarker analysis
Related Services
Discovery Biology
Explore integrated discovery biology and pharmacology services supporting target validation, disease models, and efficacy studies.
Learn More
DMPK
Optimize drug exposure and candidate selection with integrated ADME, pharmacokinetics, and PK/PD services.
Learn More
Bioanalysis
Support drug development with GLP and non-GLP bioanalytical solutions for biologics and small molecules.
Learn More
Safety Assessment
Advance candidates with comprehensive safety assessment services from investigative studies to IND-enabling programs.
Learn More
You May Also Be Interested In
Discuss Your Program with Us
Share your development goals and key challenges with our experts to define the right path forward.
Frequently Asked Questions About Digestive & GI Diseases
Digestive and gastrointestinal disorders are conditions that affect the esophagus, stomach, pancreas, small intestine, colon, or other components of the digestive system, disrupting normal digestion, motility, absorption, or immune function. They include inflammatory, structural, and functional diseases such as gastric ulcers, pancreatitis, eosinophilic esophagitis, inflammatory bowel disease (IBD), chronic constipation, and delayed gastric emptying.
Common gastrointestinal disorders include inflammatory bowel disease (Crohn's disease and ulcerative colitis), gastric ulcers, pancreatitis, eosinophilic esophagitis, chronic constipation, short bowel syndrome, and delayed gastric emptying. Many of these conditions are active areas of gastrointestinal drug discovery and development.
Gastrointestinal inflammation can result from immune dysregulation, epithelial barrier dysfunction, infections, chemical injury, genetic susceptibility, environmental factors, or changes in the gut microbiome. Preclinical models reproduce these mechanisms to evaluate the safety and efficacy of new therapies before clinical testing.
The terms gastrointestinal disorders and digestive diseases are often used interchangeably. Gastrointestinal disorders is the broader medical term describing diseases of the digestive tract, while digestive diseases is more commonly used in clinical practice, public health, and patient education.
Developing therapies for gastrointestinal disorders requires a combination of in vitro assays, physiologically relevant organoid systems, validated animal models, translational pharmacology, DMPK, bioanalysis, and safety assessment. Researchers select models and assays based on the target organ, disease mechanism, and therapeutic modality to generate data supporting clinical development and regulatory submissions.
Gastrointestinal drug development presents unique challenges due to the complexity of the digestive tract, immune signaling, barrier function, gut–brain interactions, and the influence of the microbiome. Additional challenges include identifying predictive biomarkers, evaluating gastrointestinal motility and absorption, and translating preclinical findings into meaningful clinical outcomes.
Gastrointestinal disease research relies on complementary in vitro and in vivo models to reproduce different aspects of disease biology. Common models include gastric ulcer, pancreatitis, eosinophilic esophagitis, constipation, short bowel syndrome, and inflammatory bowel disease models. IBD research specifically uses chemically induced (DSS, TNBS, oxazolone), antibody-mediated (anti-CD40), adoptive T-cell transfer, and genetically modified models to study Crohn's disease and ulcerative colitis.
Inflammatory bowel disease (IBD) is a group of chronic inflammatory gastrointestinal disorders that primarily includes Crohn's disease and ulcerative colitis. Although both conditions cause intestinal inflammation, Crohn's disease can affect any region of the digestive tract, whereas ulcerative colitis is generally limited to the colon and rectum.
The D-xylose absorption test measures intestinal absorptive function and is commonly used in preclinical studies of short bowel syndrome and other intestinal disorders. It helps evaluate therapies designed to improve nutrient absorption and intestinal function, including GLP-2 receptor agonists.
Animal models play a critical role in gastrointestinal drug development by helping researchers understand disease mechanisms, evaluate therapeutic efficacy, identify safety risks, and generate the preclinical data required to support IND applications and clinical trials.
WuXi Biology and Testing supports gastrointestinal drug development through an integrated platform spanning discovery biology, pharmacology, DMPK, bioanalysis, and safety assessment. Our capabilities include custom in vitro assays, human intestinal organoid models, validated disease models across the digestive tract, biomarker analysis, and IND-enabling studies designed to accelerate the development of therapies for gastrointestinal disorders.
Gastrointestinal drug development spans a wide range of therapeutic modalities, including small molecules, biologics, peptides, oligonucleotides, and emerging approaches such as targeted protein degraders and microbiome-based therapies. Each modality presents unique challenges related to efficacy, delivery, absorption, and safety.
Researchers use specialized in vitro and in vivo assays to assess intestinal permeability, absorption, and drug exposure. These include permeability studies, intestinal organoid models, gastric emptying assessments, intestinal transit assays, and D-xylose absorption testing.
Human intestinal organoids provide physiologically relevant three-dimensional models of the intestinal epithelium, enabling researchers to study disease biology, evaluate drug efficacy, and assess permeability and toxicity earlier in development.
Biomarkers help researchers understand disease progression, evaluate target engagement, monitor treatment response, and translate preclinical findings into clinical outcomes. Gastrointestinal studies often combine functional assays, histopathology, and molecular biomarkers to support decision-making.